CXCR7/RDC-1 Antibody - BSA Free

Western Blot: CXCR7/RDC-1 AntibodyBSA Free [NBP2-24779]

Western Blot: CXCR7/RDC-1 Antibody [NBP2-24779] - Total protein from human spleen, tonsil, lymph node and mouse spleen was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-CXCR7 in 1% BSA in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.

Western Blot: CXCR7/RDC-1 Antibody - BSA Free [NBP2-24779] -

CXCR7 expression is upregulated in middle cerebral artery occlusion (MCAO) rat ischemic penumbra brain tissue, in C6 cells under oxygen and glucose deprivation (OGD), and in the peripheral blood of a patient with acute ischemic stroke with thrombectomy. (A) Experimental procedure and timeline. (B) The modified neurological severity score (mNSS) following MCAO establishment. (C) Relative gene expression of CXCR7 in the ischemic penumbra brain tissues of the rats at 6 h, 12 h, 1, 3, and 7 days after MCAO establishment and in the sham group (n = 3). (D) Densitometric quantification of CXCR7/GAPDH. (E) Relative gene expression of CXCR7 in the C6 cells at 0, 2, 4, 6, and 8 h under hypoxia condition and in the sham group (n = 3). (F) Densitometric quantification of CXCR7/GAPDH. (G) Correlation between CXCR7 expression and mNSS scores using Pearson's correlation coefficient. (H) Levels of CXCR7 are increased in the serum of patients with acute ischemic stroke undergoing mechanical thrombectomy (n = 17) compared with that in healthy control participants (n = 10). *p < 0.05 versus the sham group Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36523152), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CXCR7/RDC-1 Antibody - BSA Free [NBP2-24779] -

CXCR7 expression is upregulated in middle cerebral artery occlusion (MCAO) rat ischemic penumbra brain tissue, in C6 cells under oxygen and glucose deprivation (OGD), and in the peripheral blood of a patient with acute ischemic stroke with thrombectomy. (A) Experimental procedure and timeline. (B) The modified neurological severity score (mNSS) following MCAO establishment. (C) Relative gene expression of CXCR7 in the ischemic penumbra brain tissues of the rats at 6 h, 12 h, 1, 3, and 7 days after MCAO establishment and in the sham group (n = 3). (D) Densitometric quantification of CXCR7/GAPDH. (E) Relative gene expression of CXCR7 in the C6 cells at 0, 2, 4, 6, and 8 h under hypoxia condition and in the sham group (n = 3). (F) Densitometric quantification of CXCR7/GAPDH. (G) Correlation between CXCR7 expression and mNSS scores using Pearson's correlation coefficient. (H) Levels of CXCR7 are increased in the serum of patients with acute ischemic stroke undergoing mechanical thrombectomy (n = 17) compared with that in healthy control participants (n = 10). *p < 0.05 versus the sham group Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36523152), licensed under a CC-BY license. Not internally tested by Novus Biologicals.